Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 2/20 | 0.61 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.61 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.61 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.61 |
| ▸ | CES2 | O00748 | 3/20 | 0.50 |
| ▸ | CES1 | P23141 | 3/20 | 0.50 |
| ▸ | NAT1 | P18440 | 2/20 | 0.50 |
| ▸ | GAPDH | P04406 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | CDC25B | P30305 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | BLM | P54132 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19420537 | 0.94 | NSD2 (0.53) | NSD2HSP90AA1HKDC1TLR9CES2 | |
| SCHEMBL6256773 | 0.87 | LTA4H (0.50) | NSD2HSP90AA1HKDC1TLR9CES2 | |
| SCHEMBL1242175 | 0.85 | CES2 (0.55) | NSD2HSP90AA1HKDC1TLR9CES2 | |
| SCHEMBL1802680 | 0.85 | NSD2 (0.73) | NSD2HSP90AA1HKDC1TLR9CES2 | |
| SCHEMBL1242176 | 0.81 | NSD2 (0.42) | NSD2HSP90AA1HKDC1TLR9CES2 | |
| Anthraquinone SCHEMBL28596353 | 0.78 | MEN1 (0.63) | NSD2HSP90AA1HKDC1TLR9CES2 | |
| SCHEMBL19409296 | 0.76 | MAPT (0.44) | NSD2HSP90AA1HKDC1TLR9CES2 | |
| SCHEMBL9562528 | 0.75 | MAPT (0.71) | NSD2HKDC1POLBMAPTRAB9A | |
| 2,3-Dibromo-1,4-Naphthoquinone SCHEMBL29475349 | 0.75 | MAPT (0.68) | NSD2CES2CES1POLBMAPT | |
| 2,3-Dibromo-1,4-Naphthoquinone SCHEMBL1240837 | 0.75 | MAPT (0.68) | NSD2CES2CES1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577315-B2 | Compositions and methods for treatment of prostate carcinoma | PELLFICURE PHARMACEUTICALS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10577315-B2 | Compositions and methods for treatment of prostate carcinoma | PELLFICURE PHARMACEUTICALS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190169122-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS | 2019-06-06 | — | — | US | disclosed |
| US-20190169122-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS | 2019-06-06 | — | — | US | disclosed |
| US-10093620-B2 | Compositions and methods for treatment of prostate carcinoma | PELLFICURE PHARMACEUTICALS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170283374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170283374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170283374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS, INC. | 2017-10-05 | — | — | US | disclosed |
| EP-3191087-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | Pellficure Pharmaceuticals, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016040896-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | PELLFICURE PHARMACEUTICALS, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| EP-0410172-A2 | 2-Halogeno-3-phenoxy-1,4-naphthoquinone derivatives | BAYER AG (DE) | 1991-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10093620-B2 | Compositions and methods for treatment of prostate carcinoma | KLK3, ACP3, NR5A1 | NSD2 2207/4885HSP90AA1 264/4885HKDC1 508/4885 |
| US-20190169122-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | KLK3, ACP3, NR5A1 | NSD2 2207/4885HSP90AA1 264/4885HKDC1 508/4885 |
| US-20170283374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROSTATE CARCINOMA | KLK3, ACP3, NR5A1 | NSD2 2207/4885HSP90AA1 264/4885HKDC1 508/4885 |
| US-10577315-B2 | Compositions and methods for treatment of prostate carcinoma | KLK3, ACP3, NR5A1 | NSD2 2207/4885HSP90AA1 264/4885HKDC1 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.